No popular authors found.
Ads by Google:

Categories

No categories found.


Get Celiac.com's E-Newsletter





Ads by Google:


Follow / Share


  FOLLOW US:
Twitter Facebook Google Plus Pinterest RSS Podcast Email  Get Email Alerts
SHARE:

Popular Articles

No popular articles found.
Celiac.com Sponsors:

Australian Researchers Begin Work on a Vaccine for Celiac Disease

Celiac.com 10/29/2002 - Dr Robert Anderson, Research Fellow at the Nuffield Department of Medicine at the University of Oxford (now based at the Royal Melbourne Hospital in Australia), and colleagues recently announced their intent to begin work on a vaccine that could cure celiac disease. The Australian teams work will be based on Dr. Andersons earlier groundbreaking Oxford research that identified the specific set of protein sequences in gluten that cause damage to the guts of those with celiac disease (see: Nature Medicine 6, 337 - 342 - 01 Mar 2000). In addition to finding a possible cure for celiac disease the teams research could open the door for a specific diagnostic test for the disease, new treatment and prevention strategies, and even the possibility of producing grains that do not contain the harmful sequences. Dr. Andersons future research will focused on proving that a specific "toxic peptide" can be used to desensitize or induce tolerance in people with celiac disease, and any vaccine would likely be the "toxic peptide" itself or a modified form of it.

Ads by Google:

The Australian team also announced their agreement for the commercialization of new celiac disease technology developed by the University of Oxford. BTG and Isis will develop diagnostic tests and treatments for gluten intolerance. BTG is a London-based technology transfer company which has bought the rights to the teams discovery, and Isis Innovation Ltd, is Oxford Universitys wholly-owned technology transfer company that was established in 1988 and is a world leader in university technology transfer. Under the terms of the Isis agreement, BTG will have exclusive access to the Universitys technology for use in the diagnosis, prevention and treatment of celiac disease. The technology is based on identification of the particular epitopes that cause priming of the immune system in celiac disease. BTG will underwrite all costs associated with the development and commercialization of the technology, and will share any revenue from commercialization of the technology with Isis and the University.

Celiac.com welcomes your comments below (registration is NOT required).












Related Articles



Comments




Rate this article and leave a comment:
Rating: * Poor Excellent
Your Name *: Email (private) *:




In Celiac.com's Forum Now:


Welcome! Here is a link to our Newbie 101 thread that you might find useful. I can only comment on those foods that I have in my home or have purchased. 1. Nutella is and it states it in the label. 2. Skippy PB is gluten-free (not stated, but ingrediants are). 3. ...

In the beginning, you might find ANY gluten free bread abhorrent. So, you might wait a few months to give yourself time to forget what wheat bread tasted like.

In my brief research, I did not find any public papers indicating villi blunting for Losartan specifically. There was research and a law suit on olmesartan (other celiac.com members have pointed out). Dr. Hart may have been making clinical observations or has access to medical research that is...

I did find a local store that carries the Canyon House brand and will give that a try. It can be tough as I live in a fairly rural area and we don't have a lot of the resources many of the more urban areas do. It is a 1 hour round trip just to get to the closest town with anything like a Trader ...

Hello, Often drugs that end in ?artan are ARBs, and they work by blocking the angiotensin receptors. I?m not sure what the exact difference is between the two medications you mention, though. Have you called the manufacturer of losartan to see if any of the fillers contain gluten? It might b...